Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
Hosted on MSN2d
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take CisplatinCisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate ...
AstraZeneca Pharma India Ltd. has received approval from CDSCO to import and sell Lynparza (Olaparib) in India. Lynparza will ...
Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...
Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...
AstraZeneca Pharma India has gained approval from India's drug regulator to import cancer treatment drug Lynparza for sale. The tablets are for use in combination therapy for patients with specific ...
Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...
AstraZeneca Pharma India has received approval from the CDSCO for Olaparib film-coated tablets, set to launch in India for ...
The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the ...
AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...
This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...
Analyze the the Stocks in Upper Circuit and Lower Circuit in NSE and invest to get a better returns. Vist India Infoline to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback